MAP2K7 and colorectal carcinoma: To test this hypothesis, five CRC cell lines were treated with U0126, a MEK/ERK inhibitor, and mithramycin A (MMA), an SP1 inhibitor that not only attenuates the binding of SP1 to DNA but also promotes the proteasome‐dependent degradation of SP1 (Figure S8A, Supporting Information).